Capvaxive on the NIP from 1 July: what changes for your patients

What just happened

From 1 July 2026, Australia has a new pneumococcal vaccine on the National Immunisation Program — and a simpler schedule to go with it.

Capvaxive is a 21-valent pneumococcal conjugate vaccine (21vPCV), the first of its kind listed in Australia. It replaces the previous approach, which required GPs and patients to navigate a sequence involving multiple different products — typically 13vPCV (Prevenar 13) followed by 23vPPSV (Pneumovax 23) — at defined time intervals. Dr Rodney Pearce described the update in RACGP newsGP coverage as simplifying “the previously complex adult pneumococcal disease schedule,” which is an understatement anyone who has tried to decipher the prior algorithm will appreciate.

The expanded NIP eligibility from 1 July covers:

• Adults aged 65 and over — the age threshold has dropped from 70, bringing in a five-year cohort who were previously not eligible for subsidised coverage
• Aboriginal and Torres Strait Islander people aged 25 and over — the previous threshold was 50, a change that addresses a longstanding equity gap in pneumococcal disease burden
• At-risk adults aged 18 and over with chronic conditions including COPD, chronic liver disease, and other conditions specified in the updated Australian Immunisation Handbook (updated 22 June 2026)

The TGA registered Capvaxive following review of the immunogenicity and safety data supporting its 21-valent formulation — covering additional serotypes compared to the 13-valent product it effectively supersedes in the NIP schedule.

---

The both-and

Why simplification matters for real-world vaccination rates

Pneumococcal vaccination for adults has had a coverage problem in Australia that is separate from any debate about vaccine science. The prior multi-product, multi-timing schedule required GP and patient coordination that was genuinely difficult to operationalise at scale. Patients and clinicians lost track of where they were in the sequence; recall systems in practices varied enormously; patients who moved between GPs often had no clear record of what had been given and when.

A single-product schedule does not automatically solve those problems, but it removes one significant layer of complexity. NCIRS data on adult vaccination coverage in Australia consistently shows that pneumococcal vaccine uptake, while improving, remains below what the disease burden justifies. Simplification is one of the evidence-based levers for improving that.

For GPs, 1 July is a natural audit trigger. The newly eligible groups — adults turning 65, Aboriginal and Torres Strait Islander patients now covered from 25, and any at-risk patients between 18 and 64 with qualifying chronic conditions who haven’t been vaccinated — are worth a targeted recall. The Australian Immunisation Register can identify what each patient has on record.

The conjugate formulation is a genuine upgrade

The shift from polysaccharide (23vPPSV/Pneumovax 23) to a conjugate vaccine (Capvaxive) for the main adult schedule is more than a serotype count change. Conjugate vaccines generate immunological memory and tend to produce more durable responses than polysaccharide-only vaccines, particularly in older adults and in people with immunocompromising conditions. The 13-valent conjugate (Prevenar 13) already demonstrated this in adults; Capvaxive extends the conjugate format to cover the 21 serotypes judged most clinically relevant in the current Australian epidemiological context.

This matters for patients in the newly eligible age groups because the quality of the immune response — not just the immediate antibody titre — is what determines protection over the years following vaccination. The TGA review process assesses this; the data supporting Capvaxive’s registration are publicly available through the TGA’s ARTG (Australian Register of Therapeutic Goods).

What happens with prior vaccination under the old schedule

The Australian Immunisation Handbook updated in June 2026 addresses catch-up scenarios for patients who received part of the old sequence. GPs will encounter patients who had Prevenar 13, Pneumovax 23, or both under varying timing protocols — the Handbook is the definitive guide for determining whether Capvaxive is needed and, if so, when.

The short answer for clinical purposes is: check the AIR, check the Handbook, and don’t assume that a prior pneumococcal vaccine means full coverage under the new standard.

---

2 cents

If you are 65 or over, or if you are Aboriginal or Torres Strait Islander and over 25, this week marks the first time a simpler, more comprehensive pneumococcal vaccine has been available to you at no cost under the NIP. It is worth raising at your next general practice appointment if you haven’t had a pneumococcal vaccine recently — or if you’re not sure whether your prior vaccination still provides adequate coverage.

For those with chronic lung or liver disease, check with your GP whether you now qualify under the at-risk category. The Australian Immunisation Handbook is the reference point; your GP can look up the current criteria and check your AIR record in the one conversation.

---

Verdict: yes — worth knowing about.

---

Sources cited

1. RACGP newsGP — New pneumococcal vaccine added to NIP. 30 June 2026. https://www1.racgp.org.au/newsgp/clinical/new-pneumococcal-vaccine-added-to-nip
2. Australian Immunisation Handbook — Pneumococcal disease. Updated June 2026. https://immunisationhandbook.health.gov.au/
3. Therapeutic Goods Administration (TGA). https://www.tga.gov.au/
4. National Centre for Immunisation Research and Surveillance (NCIRS). https://www.ncirs.org.au/